Viridian Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Viridian Therapeutics, Inc. on April 10, 2024. The report details a material definitive agreement entered into on the same date regarding the Company's headquarters lease located at 221 Crescent Street, Waltham, Massachusetts.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the new lease agreement:
- New Premises Size: 10,427 rentable square feet (reduced from 10,956 square feet).
- Base Rent: $38,232.33 per month for the first year of the extended term.
- Rent Escalation: Approximately 2.0% annual increase over the extended term.
- Tenant Improvement Allowance: Up to $104,270.
Material Changes
The Company executed a Fourth Amendment to its Lease Agreement, effective April 8, 2024. Key changes include:
- Relocation: Termination of the lease for the original suite and replacement with a new suite at the same address.
- Term Extension: The lease term is extended by five years following the New Premises Rent Commencement Date.
- Cost Adjustments: Amendments to the Company's proportionate share of operating costs and tax expenses.
Outlook, Risks, and Contingencies
The Company has secured a three-year extension option and an ongoing right of first refusal for additional space at the same address. The full text of the Amendment will be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. No specific risks or contingencies beyond the standard lease obligations were detailed in this summary.
Investor Verification Checklist
- Verify the exact "New Premises Rent Commencement Date" to determine when the $38,232.33 monthly rent obligation begins.
- Review the upcoming Form 10-Q (due after June 30, 2024) for the full text of the Fourth Amendment to Lease Agreement.
- Assess the impact of the reduced square footage (10,427 vs. 10,956) on operational capacity.
- Confirm the specific adjustments to the proportionate share of operating costs and tax expenses.